MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

KA2507

KA2507KA2507

CAS No. : 1636894-46-6

CAS No. : CAS No. : 1636894-46-61636894-46-6

MCE 国际站：KA2507

MCE 国际站：MCE 国际站：KA2507KA2507

产品活性：KA2507 是一种高效的，具有口服活性的、选择性的 HDAC6 抑制剂， 其 IC₅₀ 值为 2.5 nM。KA2507 在临床前模型中表现出抗肿瘤活性和免疫调节作用。

产品活性：产品活性：KA2507 是一种高效的，具有口服活性的、选择性的 HDAC6HDAC6 抑制剂， 其 IC₅₀IC₅₀50 值为 2.5 nM。KA2507 在临床前模型中表现出抗肿瘤活性和免疫调节作用。

研究领域：Cell Cycle/DNA Damage | Epigenetics

研究领域：研究领域：Cell Cycle/DNA DamageCell Cycle/DNA DamageCell Cycle/DNA Damage | EpigeneticsEpigeneticsEpigenetics

作用靶点：HDAC

作用靶点：作用靶点：HDACHDACHDAC

In Vitro: KA2507 did not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition.

In Vitro: In Vitro: KA2507 did not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition.

In Vivo: KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model.
KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models.
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I.
KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).

In Vivo: In Vivo: KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model.
KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models.
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I.
KA2507 exhibits poor oral bioavailability (mice 15%) and Cmaxmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg).

相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Liver Cancer Compound Library | Trichostatin A | 4-Phenylbutyric acid | Vorinostat | Valproic acid | Panobinostat | Sulforaphane | Entinostat | Romidepsin | Tucidinostat | RGFP966 | Ricolinostat | Belinostat | Tubastatin A | Tasquinimod | TMP195 | Mocetinostat | Fimepinostat | Quisinostat | TMP269 | FT895 | Tubacin | LMK-235 | Santacruzamate A | ITSA-1 | Tacedinaline | ACY-738 | PCI-34051 | SIS17

相关产品：相关产品：Drug Repurposing Compound Library PlusDrug Repurposing Compound Library PlusDrug Repurposing Compound Library Plus | Clinical Compound Library PlusClinical Compound Library PlusClinical Compound Library Plus | Bioactive Compound Library PlusBioactive Compound Library PlusBioactive Compound Library Plus | Cell Cycle/DNA Damage Compound LibraryCell Cycle/DNA Damage Compound LibraryCell Cycle/DNA Damage Compound Library | Epigenetics Compound LibraryEpigenetics Compound LibraryEpigenetics Compound Library | Histone Modification Research Compound LibraryHistone Modification Research Compound LibraryHistone Modification Research Compound Library | Anti-Cancer Compound LibraryAnti-Cancer Compound LibraryAnti-Cancer Compound Library | Clinical Compound LibraryClinical Compound LibraryClinical Compound Library | Anti-Aging Compound LibraryAnti-Aging Compound LibraryAnti-Aging Compound Library | Drug Repurposing Compound LibraryDrug Repurposing Compound LibraryDrug Repurposing Compound Library | Reprogramming Compound LibraryReprogramming Compound LibraryReprogramming Compound Library | Oxygen Sensing Compound LibraryOxygen Sensing Compound LibraryOxygen Sensing Compound Library | Anti-Breast Cancer Compound LibraryAnti-Breast Cancer Compound LibraryAnti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound LibraryAnti-Pancreatic Cancer Compound LibraryAnti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound LibraryAnti-Blood Cancer Compound LibraryAnti-Blood Cancer Compound Library | Anti-Liver Cancer Compound Library Anti-Liver Cancer Compound Library Anti-Liver Cancer Compound Library | Trichostatin ATrichostatin ATrichostatin A | 4-Phenylbutyric acid4-Phenylbutyric acid4-Phenylbutyric acid | VorinostatVorinostatVorinostat | Valproic acidValproic acidValproic acid | PanobinostatPanobinostatPanobinostat | SulforaphaneSulforaphaneSulforaphane | EntinostatEntinostatEntinostat | RomidepsinRomidepsinRomidepsin | TucidinostatTucidinostatTucidinostat | RGFP966RGFP966RGFP966 | RicolinostatRicolinostatRicolinostat | BelinostatBelinostatBelinostat | Tubastatin ATubastatin ATubastatin A | TasquinimodTasquinimodTasquinimod | TMP195TMP195TMP195 | MocetinostatMocetinostatMocetinostat | FimepinostatFimepinostatFimepinostat | QuisinostatQuisinostatQuisinostat | TMP269TMP269TMP269 | FT895FT895FT895 | TubacinTubacinTubacin | LMK-235LMK-235LMK-235 | Santacruzamate ASantacruzamate ASantacruzamate A | ITSA-1ITSA-1ITSA-1 | TacedinalineTacedinalineTacedinaline | ACY-738ACY-738ACY-738 | PCI-34051PCI-34051PCI-34051 | SIS17SIS17SIS17

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸

热门产品线：热门产品线：重组蛋白重组蛋白重组蛋白 | 化合物库化合物库化合物库 | 天然产物天然产物天然产物 | 染料试剂染料试剂染料试剂 | PROTACPROTACPROTAC | 同位素标记物同位素标记物同位素标记物 | 寡核苷酸寡核苷酸寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

Trending products：Trending products：Recombinant ProteinsRecombinant ProteinsRecombinant Proteins | Bioactive Screening LibrariesBioactive Screening LibrariesBioactive Screening Libraries | Natural ProductsNatural ProductsNatural Products | Dye ReagentsDye ReagentsDye Reagents | PROTACPROTACPROTAC | Isotope-Labeled CompoundsIsotope-Labeled CompoundsIsotope-Labeled Compounds | OligonucleotidesOligonucleotidesOligonucleotides

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。

品牌介绍:品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。